all relevant points Dave.... I suspect you and
Post# of 30028
I suspect you and a few other were not surprised at all to hear no revenue guidance on LymPro today...
what will LymPro's RUO revenue really be worth - short - mid - long term
what is the true reason why Jason Napadano dropped his LymPro revenue guidance to an eye popping $1-Mil. in FY15 and a measly $3.5-Mil. in FY16 when projecting a $0.20 pps for FY14
what is the real status with LymPro's CPT codes for insurance billing
how much real competition does LymPro actually face with more visible and highly publicized AZ diag. tests (one particularly which recently claimed 100% efficiency)
I for one believe the shareholders deserved a few minutes from Gerald on LymPro to address a few of these key issues
but time was limited, as an 8:00 AM CC with 1 day prior notice caught most people busy commuting, getting to work, in trains, cars and buses, and only 10 minutes provided before the bell for Q/A, all of which went to 2 preselected candidates anyways
....felt rushed - like the "bums rush" CC